OBJECTIVE： To investigate the effectiveness and safety of 2 kinds of proton pump inhibitors in the treatment of coronary heart disease （CHD）. METHODS： In retrospective study， a total of 92 patients with CHD were selected from our hospital during Jun. 2015-May 2016， and then divided into rabeprazole group （30 cases）， esomeprazole group （32 cases） and control group （30 cases） according to therapy plan. Control group received basic therapy plan. Rabeprazole group and esomeprazole group were additionally given sodium rabeprazole enteric-coated tablets and Esomeprazole magnesium enteric-coated tablets 20 mg， po， bid， on the basis of control group. A treatment course lasted for 30 d， and both medication groups received 2 courses of treatment. Blood uric acid levels， urine pH values， blood ion levels （Na+， K+， Ca2+， Cl－） were detected before and after treatment. The occurrence of cardiovascular adverse events， coronary adverse events and other adverse events were observed in 2 groups during treatment. RESULTS： Before treatment， there was no statistical significance in above indexes among 3 groups （P＞0.05）. After treatment， the levels of blood uric acid， K+ （except for control group）， Ca2+ and Cl－ were decreased significantly， while urine pH values and blood Na+ levels were increased significantly； the levels of blood uric acid and Ca2+ in rabeprazole group and esomeprazole group were significantly lower than control group， while urine pH value and blood Na+ level were significantly higher than control group， with statistical significance （P＜0.05）. After treatment， the level of blood uric acid in rabeprazole group was significantly lower than esomeprazole group， with statistical significance （P＜0.05）. But there was no statistical significance in urine pH values or ion levels between 2 groups （P＞0.05）. Compared with control group， the incidence of acute thrombosis in rabeprazole group and esomeprazole group were decreased significantly， and the incidence of joint swelling and pain were increased significantly， with statistical significance （P＜0.05）. There was no statistical significance in the incidence of coronary adverse events among 3 groups （P＞0.05）. CONCLUSIONS： Rabeprazole and esomeprazole can significantly reduce the level of blood uric acid and the incidence of acute thrombosis， increase urine pH value and blood Na+ levels， decrease blood Ca2+ level and increase the risk of fracture or hypocalcemia in patients with CHD. Therefore， the dosage regimen should be adjusted according to the specific situation of patients in clinical practice